|
Daily Medical Update
Benign Prostatic Hyperplasia (Alpha-blockers, 5-ARIs)
Thursday, March 05, 2026
|
🔬 Practice‑Changing Findings
Evidence from RCTs and meta‑analyses published in the last 12 months.
|
The French Journal of Urology (2025) - Practice Guideline
Key Findings
- Guideline recommendations prioritize alpha-blockers for rapid symptom relief, with stronger support for adding 5-ARIs in men with enlarged prostates and progression risk.
- Updated stepwise pathways improved alignment of treatment intensity with baseline risk versus one-size symptom-only prescribing.
📋 Practice Implication: At the first follow-up after alpha-blocker start, add prostate-volume/progression-risk assessment so you can escalate to combination therapy earlier in appropriate patients.
|
The French Journal of Urology (2025) - Practice Guideline
Key Findings
- Guideline-concordant pathways improved successful trial-without-catheter rates and reduced early recurrent retention compared with delayed, non-structured follow-up.
- Guideline-based pathways reduced recurrent retention risk signals compared with unstructured delayed follow-up approaches.
📋 Practice Implication: Use a fixed post-retention workflow (catheter plan + medication adjustment + booked trial-without-catheter date) before discharge from primary care follow-up.
|
Neurourology and Urodynamics (2026) - Randomized Controlled Trial
Key Findings
- Among men already treated for BPH, vibegron improved urgency/frequency outcomes versus placebo over 24 weeks.
- Safety outcomes were favorable, with no major excess urinary-retention signal versus control in the trial population.
📋 Practice Implication: For men still bothered by storage symptoms despite BPH medication, trial a beta-3 agonist before assuming medication failure and escalating to procedure referral.
|
BJU International (2026) - Systematic Review/Meta-Analysis
Key Findings
- Pooled randomized data showed preoperative 5-ARI exposure reduced perioperative bleeding-related outcomes during TURP versus comparator care.
- Benefit signals were stronger in cohorts at higher baseline risk for operative blood loss and transfusion.
📋 Practice Implication: When co-managing TURP candidates, proactively review 5-ARI status with urology to improve perioperative bleeding-risk planning rather than addressing this only at pre-op clearance.
|
Urology (2026) - Systematic Review/Meta-Analysis
Key Findings
- Water vapor thermal therapy improved LUTS outcomes in both large and average gland groups, but effect size and durability were lower in very large prostates.
- Retreatment risk increased in larger-volume cohorts versus average-size cohorts across pooled studies.
📋 Practice Implication: Before minimally invasive referral, measure or confirm prostate volume so counseling includes realistic retreatment probability and avoids undershooting definitive options in very large glands.
|
|
Recent BPH evidence supports risk-stratified medication escalation rather than symptom-only treatment. Guideline updates reinforce pairing alpha-blockers with 5-ARIs in men at progression risk, while newer trial data support targeted add-on therapy for persistent storage symptoms. For referral decisions, prostate volume and procedure type increasingly predict durability and complication trade-offs.
|
|